TY - JOUR
T1 - HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software
AU - Royle, Louise
AU - Campbell, Matthew P.
AU - Radcliffe, Catherine M.
AU - White, Dawn M.
AU - Harvey, David J.
AU - Abrahams, Jodie L.
AU - Kim, Yun Gon
AU - Henry, George W.
AU - Shadick, Nancy A.
AU - Weinblatt, Michael E.
AU - Lee, David M.
AU - Rudd, Pauline M.
AU - Dwek, Raymond A.
PY - 2008/5/1
Y1 - 2008/5/1
N2 - We present a robust, fully automatable technology platform that includes computer software for the detailed analysis of low femtomoles of N-linked sugars released from glycoproteins. Features include (i) sample immobilization in 96-well plates, glycan release, and fluorescent labeling; (ii) quantitative HPLC analysis, including monosaccharide sequence, linkage, and arm-specific information for charged and neutral glycans; (iii) automatic structural assignment of peaks from HPLC profiles via web-based software that accesses our database (GlycoBase) of more than 350 N-glycan structures, including 117 present in the human serum glycome; and (iv) software (autoGU) that progressively analyzes data from exoglycosidase digestions to produce a refined list of final structures. The N-glycans from a plate of 96 samples can be released and purified in 2 or 3 days and profiled in 2 days. This strategy can be used for (i) identification and screening of disease biomarkers and (ii) monitoring the production of therapeutic glycoproteins, allowing optimization of production conditions. This technology is also suitable for preparing released glycans for other analytical techniques. Here we demonstrate its application to rheumatoid arthritis using 5 μl of patient serum.
AB - We present a robust, fully automatable technology platform that includes computer software for the detailed analysis of low femtomoles of N-linked sugars released from glycoproteins. Features include (i) sample immobilization in 96-well plates, glycan release, and fluorescent labeling; (ii) quantitative HPLC analysis, including monosaccharide sequence, linkage, and arm-specific information for charged and neutral glycans; (iii) automatic structural assignment of peaks from HPLC profiles via web-based software that accesses our database (GlycoBase) of more than 350 N-glycan structures, including 117 present in the human serum glycome; and (iv) software (autoGU) that progressively analyzes data from exoglycosidase digestions to produce a refined list of final structures. The N-glycans from a plate of 96 samples can be released and purified in 2 or 3 days and profiled in 2 days. This strategy can be used for (i) identification and screening of disease biomarkers and (ii) monitoring the production of therapeutic glycoproteins, allowing optimization of production conditions. This technology is also suitable for preparing released glycans for other analytical techniques. Here we demonstrate its application to rheumatoid arthritis using 5 μl of patient serum.
UR - http://www.scopus.com/inward/record.url?scp=41449087577&partnerID=8YFLogxK
U2 - 10.1016/j.ab.2007.12.012
DO - 10.1016/j.ab.2007.12.012
M3 - Article
C2 - 18194658
AN - SCOPUS:41449087577
VL - 376
SP - 1
EP - 12
JO - Analytical Biochemistry
JF - Analytical Biochemistry
SN - 0003-2697
IS - 1
ER -